Brief: Terns Pharmaceuticals Q2 Net Income USD -22.736 Million Vs. IBES Estimate USD -26 Million
05/08/2024 21:05
Aug 05 (Reuters) - Terns Pharmaceuticals Q2 operating expenses USD 25.537 million. * Q2 income from operations USD -25.537 million vs. IBES estimate USD -27.9 million * Q2 basic EPS USD -0.31 * Q2 pretax profit USD -22.675 million vs. IBES estimate USD -26 million
Recent news on Terns Pharmaceuticals
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
Brief: Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period To Acquire Terns Pharmaceuticals
Brief: Merck Begins Tender Offer To Acquire Terns Pharmaceuticals, Inc.